NCT01621386View on ClinicalTrials.gov

Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

March 31, 2016

Conditions
Asthma
Interventions
DRUG

Montelukast

Administered orally as a single daily 10 mg dose for 2 weeks

DRUG

Prednisone

Administered orally as a single daily 20 mg dose for 2 weeks

Trial Locations (1)

27705

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Hal C Charles

OTHER

NCT01621386 - Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513) | Biotech Hunter | Biotech Hunter